PT - JOURNAL ARTICLE AU - Cogan, Guillaume AU - Daida, Kensuke AU - Billingsley, Kimberley J. AU - Tesson, Christelle AU - Forlani, Sylvie AU - Jornea, Ludmila AU - Arnaud, Lionel AU - Tissier, Laurene AU - LeGuern, Eric AU - Singleton, Andrew B. AU - Ferrien, Mélanie AU - Gervais Bernard, Hélène AU - Lesage, Suzanne AU - Blauwendraat, Cornelis AU - Brice, Alexis TI - Long-read sequencing unravels the complexity of structural variants in <em>PRKN</em> in two individuals with early-onset Parkinson’s disease AID - 10.1101/2024.05.02.24306523 DP - 2024 Jan 01 TA - medRxiv PG - 2024.05.02.24306523 4099 - http://medrxiv.org/content/early/2024/05/03/2024.05.02.24306523.short 4100 - http://medrxiv.org/content/early/2024/05/03/2024.05.02.24306523.full AB - Background PRKN biallelic pathogenic variants are the most common cause of autosomal recessive early-onset Parkinson’s disease (PD). However, the variants responsible for suspected PRKN-PD individuals are not always identified with standard genetic testing.Objectives Identify the genetic cause in two siblings with a PRKN-PD phenotype using long-read sequencing (LRS).Methods The genetic investigation involved standard testing using successively multiple ligation probe amplification (MLPA), Sanger sequencing, targeted sequencing, whole-exome sequencing and LRS.Results MLPA and targeted sequencing identified one copy of exon four in PRKN but no other variants were identified. Subsequently, LRS unveiled a large deletion encompassing exon 3 to 4 on one allele and a duplication of exon 3 on the second allele; explaining the siblings’ phenotype. MLPA could not identify the balanced rearrangement of exon 3.Conclusions This study highlights the potential utility of long-read sequencing in the context of unsolved typical PRKN-PD individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Intramural Research Programs of the National Institute on Aging (NIA). This work was also supported by the Fondation pour la Recherche Medicale (FRM, MND202004011718), the Fondation de France, la Federation pour la Recherche sur le Cerveau (FRC), France-Parkinson Association, and the French program "Investissements d'avenir" (ANR-10-IAIHU-06).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local ethics committee (Number 44,814; INSERM, CCPPRB of Groupe Hospitalier Pitie-Salpetriere, Paris, France) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used in the preparation of this article are available upon request to the authors.